NASDAQ · Biotechnology

Cingulate Inc. (CING) Stock

$4.89 +0.20% NASDAQ: CING Healthcare

Valuation

MetricValue
Price$4.89
Market Cap$65.86M
P/E Ratio-0.95
P/B Ratio1.10
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$11.89
52-Week Low$3.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-238.41%
ROA-87.09%
ROCE-101.98%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.27
Current Ratio1.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-18.0M$-23.0M$-16.0M$-20.0M
Net Profit$-21.0M$-18.0M$-24.0M$-17.0M$-22.0M
EPS$-55.80$-31.20$-311.99$-10.20$-4.13
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$23.0M$11.0M$3.0M$15.0M$15.0M
Total Liabilities$2.0M$8.0M$10.0M$7.0M$13.0M
Cash$16.0M$5.0M$0$12.0M$11.0M
Borrowings$1.0M$6.0M$4.0M$5.0M$9.0M

Latest News

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® GlobeNewswire · Jul 2, 2026 Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 GlobeNewswire · Jun 16, 2026 Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 TMX Newsfile · Jun 4, 2026 Cingulate Receives Complete Response Letter from FDA for CTx-1301 GlobeNewswire · Jun 2, 2026 CING: Building Its Cash Position Zacks Small Cap Research · May 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-16.0M$-15.0M$-18.0M$-17.0M
Investing Cash Flow$-2.0M$0$0$0$0
Financing Cash Flow$7.0M$0$0$0$0
Net Cash Flow$15.0M$-11.0M$-5.0M$12.0M$-1.0M
Free Cash Flow$-11.0M$-16.0M$-15.0M$-19.0M$-17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.12
EV / EBITDA0.22
FCF Yield-32.66%
Quick Ratio3.50
Interest Coverage20.43
Return 1Y1.55%
Return 3Y-97.58%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLRAllarity Therapeutics, Inc. $0.99 +0.82% -1.33 $15.75M 0.00%
BCTXBriaCell Therapeutics Corp. $3.91 -0.26% -0.33 $34.02M 0.00%
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%
ENTOEntero Therapeutics, Inc. $2.85 -5.00% -0.82 $13.58M 0.00%

About Cingulate Inc.

Cingulate Inc. is led by CEO Shane J. Schaffer, employs 13 people, headquartered in US, publicly traded since 2021.

Cingulate Inc. (CING) stock trades at $4.89 with a market capitalization of $65.86M. The stock is valued at a price-to-earnings (P/E) ratio of -0.95, price-to-book of 1.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.16 and $11.89, and currently trades 58.9% below its 52-week high.

On profitability, Cingulate Inc. generates a return on equity (ROE) of -238.41%, return on capital employed of -101.98%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides